AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Growth in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 7,013,343 shares, an increase of 5,016.3% from the May 14th total of 137,078 shares. Currently, 48.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 123,199,850 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AIM. Corient Private Wealth LLC acquired a new stake in shares of AIM ImmunoTech in the 2nd quarter valued at approximately $87,000. DRW Securities LLC raised its position in shares of AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares during the period. Finally, Sabby Management LLC acquired a new stake in shares of AIM ImmunoTech in the 3rd quarter valued at approximately $79,000. 12.02% of the stock is currently owned by institutional investors and hedge funds.

AIM ImmunoTech Stock Performance

AIM ImmunoTech stock opened at $0.44 on Thursday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.10. AIM ImmunoTech has a 1 year low of $0.21 and a 1 year high of $20.35. The company has a market cap of $6.37 million, a PE ratio of -0.07 and a beta of 1.18. The company’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.91.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. Equities analysts anticipate that AIM ImmunoTech will post -0.63 earnings per share for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their target price on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, AIM ImmunoTech currently has a consensus rating of “Buy” and a consensus price target of $9.00.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.